Drugging all RAS isoforms with one pocket.
Kessler, D., Bergner, A., Bottcher, J., Fischer, G., Dobel, S., Hinkel, M., Mullauer, B., Weiss-Puxbaum, A., McConnell, D.B.(2020) Future Med Chem 12: 1911-1923
- PubMed: 32779487 
- DOI: 10.4155/fmc-2020-0221
- Primary Citation of Related Structures:  
6ZIO, 6ZIR, 6ZIZ, 6ZJ0, 6ZL3, 6ZL5, 6ZLI - PubMed Abstract: 
Activating mutations in the three human RAS genes, KRAS , NRAS and HRAS , are among the most common oncogenic drivers in human cancers. Covalent KRAS G12C inhibitors, which bind to the switch II pocket in the 'off state' of KRAS, represent the first direct KRAS drugs that entered human clinical trials ...